Working… Menu

Safety Study of NNZ-2566 in Healthy Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00961779
Recruitment Status : Completed
First Posted : August 19, 2009
Last Update Posted : October 7, 2014
Information provided by (Responsible Party):
Neuren Pharmaceuticals Limited

Brief Summary:
The purpose of this study is to obtain evidence of the safety of NNZ-2566 in healthy female volunteers and to determine the pharmacokinetics (PK) of NNZ-2566 in healthy female volunteers.

Condition or disease Intervention/treatment Phase
Brain Injuries, Traumatic Drug: NNZ-2566 Drug: Placebo Phase 1

Detailed Description:

To obtain evidence of the safety of NNZ-2566 in healthy female volunteers, compared to placebo when administered as a 10 minute intravenous (i.v.) bolus infusion, and when administered as a 10-minute bolus infusion immediately followed by a continuous 72-hour maintenance infusion.

To determine the blood pharmacokinetics (PK) of an intravenous dose of NNZ-2566 in healthy female volunteers when administered as a 10-minute bolus infusion, and when administered as a 10-minute bolus followed by a continuous 72-hour maintenance infusion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability and PK of NNZ-2566 in Healthy Females, When Administered as a Loading Dose (10-Min), and as a Loading Dose Followed by a Maintenance Dose (72-Hr).
Study Start Date : March 2010
Actual Primary Completion Date : August 2010
Actual Study Completion Date : September 2010

Arm Intervention/treatment
Placebo Comparator: Placebo (Normal saline infusion) Drug: Placebo
Normal saline infusion
Other Name: Sodium Chloride 0.9% Injection

Experimental: NNZ-2566
NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
Drug: NNZ-2566
Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
Other Name: Experimental name: NNZ-2566

Primary Outcome Measures :
  1. Incidence of AEs and SAEs [ Time Frame: Through to Day 7 post end of study drug infusion or until resolved ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged between 18 years and 50 years (inclusive).
  • Females only.
  • Weight 50 to 105 kg
  • BMI of 18 to 30 kg/m2.
  • General Health: Healthy, determined by a medical history with particular attention to:

    • a drug history identifying any known drug allergies and the presence of drug abuse;
    • any chronic use of medication; and
    • a thorough review of body systems. This will also be determined by having no clinically significant abnormal findings on physical examination, which includes an electrocardiogram (ECG), which in the opinion of the Investigator would jeopardize the safety of the subject or impact on the validity of the study results.
  • Venous Access: Volunteers with adequate venous access in their left and right arm to allow collection of blood samples and drug administration.
  • Language: Fluent in the English language.
  • Informed Consent: Have voluntarily given written informed consent to participate in this study.

Exclusion Criteria:

  • Pregnant and lactating females are excluded from participating in the study.
  • History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations.
  • History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or hematological disorders.
  • Any history of asthma during the last 10 years.
  • A creatinine clearance of less than 75 mL/min.
  • Any predisposing condition that might interfere with the absorption, distribution, metabolism, and/or excretion of the investigational product.
  • History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation.
  • History of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or demonstration of HIV antibodies.
  • Pregnancy.
  • Any evidence of organ dysfunction, or any clinically significant clinical laboratory value, including a liver function test (LFT) > 1.5 x upper limit of normal (ULN).
  • Difficulty abstaining from alcohol during the 48 hours prior to dose administration and until completion of blood sampling at exit assessment.
  • History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or positive urine drug screen for drugs of abuse.
  • Difficulty in abstaining from any prescription medications for 14 days prior to dose administration and for the duration of the study.
  • Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements for 14 days prior to dose administration and for the duration of the study, (with the exception of occasional analgesia, vitamin and other nutrient supplement use, at the discretion of the Investigator).
  • Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines, (e.g., coffee, tea, cola and chocolate) during the 24 hours prior to dose administration and whilst confined at the clinical study facility.
  • History of any psychiatric illness which may impair the ability to provide written informed consent.
  • Poor protocol compliers or those unlikely to attend.
  • Receipt of any drug as part of a research study within 30 days of initial dose administration in this study.
  • Standard blood donation (usually 550 mL) within the 12-week period before dose administration.
  • Unusual dietary habits and excessive or unusual vitamin intakes.
  • Vaccination or immunizations within 30 days of initial dose administration.
  • QT/QTc Exclusions i.e., a marked baseline prolongation of corrected QT interval > 450 ms in two ECGs, or a history of risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00961779

Layout table for location information
Australia, Victoria
Nucleus Network
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Neuren Pharmaceuticals Limited
Layout table for investigator information
Study Director: Douglas J Wilson, MB ChB, PhD Neuren Pharmaceuticals Ltd
Layout table for additonal information
Responsible Party: Neuren Pharmaceuticals Limited Identifier: NCT00961779    
Other Study ID Numbers: Neu-2566-HV-004
First Posted: August 19, 2009    Key Record Dates
Last Update Posted: October 7, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injuries, Traumatic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries